Endotoxin tolerance, a key mechanism for suppressing excessive inflammatory cytokine production, is induced by prior exposure of macrophages to Toll-like receptor (TLR) ligands. Induction of cross-tolerance to endotoxin by endogenous cytokines has not been investigated. Here we show that prior exposure to tumor necrosis factor (TNF) induced a tolerant state in macrophages, with less cytokine production after challenge with lipopolysaccharide (LPS) and protection from LPS-induced death. TNF-induced cross-tolerization was mediated by suppression of LPS-induced signaling and chromatin remodeling. TNF-induced cross-tolerance was dependent on the kinase GSK3, which suppressed chromatin accessibility and promoted rapid termination of signaling via the transcription factor NF-B by augmenting negative feedback by the signaling inhibitors A20 and IB. Our results demonstrate an unexpected homeostatic function for TNF and a GSK3-mediated mechanism for the prevention of prolonged and excessive inflammation.
A r t i c l e s
Cells of the innate immune response sense microbial infection or tissue damage and produce key inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin 6 (IL-6). Among the most potent inducers of inflammatory cytokine production are Toll-like receptors (TLRs) that sense microbial products and transduce inflammatory signals via the transcription factor NF-κB and mitogen-activated protein kinase (MAPK) pathways 1, 2 . Abundant inflammatory cytokine production results in excessive inflammation and associated tissue damage and contributes to the pathogenesis of inflammatory disorders. Accordingly, the production of inflammatory cytokines is tightly regulated by various mechanisms that modulate the intensity of inflammation and promote its eventual resolution and the return of tissue homeostasis 3 . Many of the mechanisms that dampen inflammation are induced by inflammatory stimuli themselves and thus function as part of feedback loops that allow finetuning of inflammatory responses.
One of the most effective protective mechanisms that suppresses inflammatory cytokine production is endotoxin tolerance. This is a phenomenon whereby prior exposure of cells or organisms to lipopolysaccharide (LPS) results in substantial suppression of the production of inflammatory cytokines and protection from toxicity and lethality after subsequent challenge with endotoxin. Microbial products that stimulate other TLRs such as TLR2 can induce cross-tolerance to LPS. Monocytes and macrophages are the principal cells involved in endotoxin tolerance in vivo, and tolerization of these cells has been studied extensively 4 . Endotoxin tolerance selectively prevents toxicity associated with excessive cytokine production while allowing beneficial TLR-induced responses, such as the production of antimicrobial peptides, to proceed. An important mechanism of endotoxin tolerance is the suppression of TLR signaling, which is achieved by the induction of signaling inhibitors, such as SOCS1, IRAK-M and SHIP-1, and downregulation of components of the TLR signaling pathway 4 . Diminished TLR signaling cannot explain the preserved induction of genes encoding molecules that cannot be tolerized, and published work has clarified that chromatin modifications, including changes in histone marks and nucleosome remodeling, have an important role in selective gene expression in endotoxin tolerance [5] [6] [7] . Repressive changes at the chromatin level can act together with diminished signaling to effectively downregulate the expression of genes encoding inflammatory cytokines.
TNF is a potent proinflammatory cytokine. It can drive local inflammation by activating tissue and endothelial cells, as well as infiltrating cells of the immune response, and can also act systemically, such as by mediating many of the deleterious effects of endotoxin toxicity. The predominantly activating role of TNF in innate immunity and host defense, and in chronic inflammation associated with diseases such as rheumatoid arthritis, is well established. However, anti-inflammatory effects of TNF have also been described [8] [9] [10] [11] [12] [13] , and TNF has a role in restraining inflammation in animal models of systemic lupus erythematosus and multiple sclerosis 14, 15 . The mechanisms by which TNF limits inflammation are minimally understood.
Glycogen synthase kinase 3-α (GSK3α) and GSK3β are serinethreonine kinases that are broadly expressed and constitutively active in most cell types, including cells of the immune response [16] [17] [18] . GSK3 activity is regulated by various immunoreceptors, such as TLRs, cytokine receptors and antigen receptors, and an important role for GSK3 in regulating immune and inflammatory responses has been established 19 . GSK3 regulates the activity of various transcription factors important in inflammation and cytokine production, including NF-κB, AP-1, CREB, NFAT, β-catenin and STAT proteins. Although GSK3 typically inactivates its substrates 16 , its function is context dependent, and it has been shown to activate or inhibit NF-κB A r t i c l e s depending on the cell type and experimental conditions [19] [20] [21] [22] [23] [24] . A proinflammatory function for GSK3 has been demonstrated and linked to GSK3-mediated regulation of the balance of the production of proinflammatory cytokines versus anti-inflammatory cytokines [16] [17] [18] [19] . However, there are several clear-cut examples of an anti-inflammatory function for GSK3 (refs. 19,25-29) . There is little understanding of the mechanistic basis of the differences in and context-dependent regulation of inflammation and NF-κB activity by GSK3.
Investigation of TNF function has focused mainly on its acute effects on cell activation and inflammation. We reasoned that, similar to other potent inflammatory activating receptors such as TLRs, TNF receptors (TNFRs) induce feedback inhibitory mechanisms that restrain and fine-tune inflammation. Such feedback inhibition would be particularly important in the regulation of cells that are not directly contacted by microbial products during infection and in settings of sterile inflammation. Several sterile inflammatory conditions associated with TNF production have been suggested to induce a tolerancelike state in monocytes 4, [30] [31] [32] , and thus we investigated whether TNF can induce an endotoxin tolerance-like state; that is, selective hyporesponsiveness and diminished inflammatory cytokine production after secondary TLR challenge. To maximize the physiological relevance for human inflammatory conditions, we used primary human monocytes and macrophages that have a key role in human inflammatory diseases and in endotoxin tolerance 4, 33 and extended our work to a mouse system to obtain confirmatory genetic evidence and test the in vivo relevance of our findings. We found that, similar to classical LPS-induced endotoxin tolerance, pretreatment with TNF selectively diminished cytokine production in response to subsequent LPS challenge and a low dose of TNF protected mice from the lethal effects of subsequent challenge with a high dose of LPS. Pretreatment with TNF attenuated TLR4-induced signaling and suppressed chromatin remodeling at the IL6 locus. These suppressive effects were mediated by GSK3, which promoted feedback inhibition of TLR4 signaling by the signaling inhibitors A20 and IκBα. This represents, to our knowledge, the first report of induction of cross-tolerance to endotoxin, including epigenetic regulation that provides transcriptional memory, by an endogenous cytokine. Our findings show unexpected suppressive functions and mechanisms induced by TNF and indicate that GSK3 is a key regulator of macrophage tolerance.
RESULTS

TNF induces cross-tolerance to endotoxin
To determine whether TNF can induce cross-tolerance to endotoxin, we pretreated primary human macrophages with LPS or TNF and challenged them with LPS, then measured subsequent cytokine production (Fig. 1a) . Consistent with published reports describing LPS-induced endotoxin tolerance, pretreatment with LPS nearly completely inhibited IL-6 production after secondary LPS challenge in primary human macrophages; 6 h of pretreatment with LPS was sufficient to substantially suppress subsequent IL-6 production (Fig. 1b) . Pretreatment with TNF also blunted IL-6 production in response to secondary LPS stimulation in a time-dependent manner (Fig. 1b) . Twenty-four hours of pretreatment with TNF was needed to substantially block IL-6 production in response to secondary LPS challenge. The TNF-induced attenuation of LPSinduced IL-6 production was highly reproducible (Fig. 1b,c) ; we did not observe substantial toxicity or more death for TNF-treated monocytes (Supplementary Fig. 1 ). Pretreatment with TNF also attenuated TLR2 responses (Supplementary Fig. 2 ) and was more effective than was pretreatment with other members of the TNF family ( Supplementary Fig. 3 ).
To determine whether pretreatment with TNF altered LPS responses at the level of gene expression, we measured mRNA by real-time quantitative PCR. Pretreatment with TNF, similar to pretreatment with LPS, suppressed subsequent LPS-induced expression of mRNA for IL-6, TNF, IL-1β and inducible nitric oxide synthase ( Fig. 1d and Supplementary Fig. 4 ). Similar to the gene-specific regulation observed in LPS-induced endotoxin tolerance 4, 5 , mRNA for the formyl peptide receptor FPR1 and mRNA for the chemokine CCL5 (RANTES) were induced by secondary LPS challenge in TNFpretreated cells. Thus, similar to their expression in LPS-tolerized macrophages, the expression of only a subset of LPS-inducible genes, including genes encoding proinflammatory cytokines, was selectively suppressed in TNF-pretreated human macrophages. Blocking TNF Supplementary Fig. 4 ). Fig. 5 ).
These results indicate that the TNF-induced effects were mediated by TNF and not by contaminating LPS, which was negligible. Overall, the results suggest that pretreatment with TNF induces a state resembling LPS-induced endotoxin tolerance, with selective suppression of TLR-induced expression of genes encoding inflammatory cytokines, in human macrophages.
Attenuation of inflammatory responses in mice
We used mouse bone marrow-derived macrophages (BMDMs) to extend our investigation of TNF-induced cross-tolerance. Pretreatment of BMDMs with TNF induced tolerization of IL-6 production in a dose-dependent manner (Fig. 2a) ; induction of IL-6 protein and mRNA was suppressed in TNF-tolerized BMDMs (Fig. 2a,b) . In BMDMs from mice deficient in TNFRs, LPS induced tolerance, but TNF did not (Fig. 2c) . These results indicate that, consistent with the literature 4 , LPS-induced tolerance was not dependent on autocrine TNF, and establish that TNF-induced cross-tolerance is mediated by TNFRs. To examine the physiological relevance of TNF-induced tolerance in vivo, we pretreated mice intravenously with 2 µg TNF and, after 1 d, challenged them with 200 µg LPS by intraperitoneal injection, then measured serum concentrations of TNF and IL-6. LPSinduced TNF production in vivo was 91% lower in mice that had been pretreated with TNF (Fig. 2d) ; pretreatment with TNF was almost as effective as pretreatment with LPS in suppressing TNF production after subsequent in vivo LPS challenge (Fig. 2d) . Serum IL-6 concentrations were also significantly lower after in vivo LPS challenge of TNF-pretreated mice (Fig. 2d) . Because LPS-induced TNF mediates LPS-induced death, we next determined whether a low dose of TNF conferred protection against the lethal effects of a subsequent high dose of LPS. All control mice that had been pretreated with PBS (vehicle control) died within 30 h of high-dose LPS challenge, whereas mice pretreated with TNF survived (Fig. 2e) . Thus, similar to results obtained with LPS, TNF-induced tolerance suppressed inflammatory cytokine production and conferred protection from toxicity induced by a high dose of LPS in vivo.
TNF inhibits TLR signaling and induces A20
One characteristic of LPS-induced tolerance is suppression of TLRinduced signaling. Thus, we compared the effects of pretreatment with TNF or LPS on signal transduction elicited by subsequent LPS stimulation. Nontolerized primary human macrophages responded to LPS stimulation with robust and prolonged degradation of IκBα and transient phosphorylation of the MAPKs p38, Erk and Jnk (Fig. 3a) .
As expected for macrophages tolerized with moderate concentrations of LPS (10 ng/ml), LPS-induced degradation of IκBα was abrogated almost completely and activation of MAPKs was much lower (Fig. 3a) . Activation of MAPKs was diminished to a similar extent in TNF-tolerized cells and LPS-tolerized cells. In contrast to IκBα degradation in LPS-tolerized cells, in TNF-tolerized macrophages, the initial phase of LPS-induced IκBα degradation was nearly intact (Fig. 3a) . However, in contrast to IκBα in control cells (Fig. 3a) , in TNF-tolerized macrophages, IκBα protein was rapidly restored to the amount present before stimulation (Fig. 3a) . IκBα rapidly returned to baseline 60 min after LPS stimulation in tolerized macrophages but not in control nontolerized macrophages ( Fig. 3a and data not shown (ten independent experiments with different blood donors)). Thus, in TNF-tolerized macrophages, the initial LPS-induced signal for IκBα degradation was mostly intact, but NF-κB signaling was terminated very quickly by the well-established IκBα-mediated post-activation repression mechanism 34 . We next investigated whether TNF induced expression of the signaling inhibitors SOCS1, SOCS3, IRAK-M and SHIP-1, which have been linked to LPS-induced tolerance 4 . Primary stimulation with LPS rapidly induced higher expression of SOCS1 and SOCS3 (Fig. 3b) that preceded or coincided with the development of tolerance at 6 h (Fig. 1b) . Stimulation with LPS resulted in only slightly higher expression of IRAK-M and SHIP-1 in human macrophages (Fig. 3b,c and Supplementary Fig. 6 ). In contrast to LPS, TNF minimally induced the expression of SOCS1 and SOCS3 but did induce a delayed increase in SHIP-1 and IRAK-M (Fig. 3b,c and Supplementary Fig. 6 ). However, induction of SHIP-1 and IRAK-M protein by TNF was modest and was not present in all donors, which suggests that SHIP-1 and IRAK-M may not be sufficient to induce tolerance. Therefore, we analyzed the A r t i c l e s expression of other known inhibitors of TLR signaling, including A20, which inhibits proximal steps in TLR signaling. TNF induced delayed but sustained expression of A20 mRNA and substantially increased A20 protein expression, with a mean 23-fold increase in A20 protein at 24 h (Fig. 3b,c and Supplementary Fig. 6 ) that coincided with the development of TNF-induced cross-tolerance (Fig. 1b) . We consistently observed robust and sustained TNF-induced expression of A20 protein (Supplementary Fig. 6 ), which suggested a role for A20 in mediating TNF-induced tolerance. The induction of A20 expression by LPS was similar to its induction by TNF (Fig. 3c) , and on average, LPS increased A20 protein expression 11-fold by 24 h (Supplementary Fig. 6 ). This suggested that A20 can contribute to LPS-induced tolerance in human macrophages, although an effect of A20 deficiency on LPS-induced tolerance has not been detected in mouse systems 35 . Knockdown of A20 expression mediated by small interfering RNA reversed TNF-induced tolerization of IL-6 expression ( Fig. 3d) and partially reversed LPSinduced tolerization of IL-6 expression (Fig. 3d) . These results support the proposal of a role for A20 in mediating the lower cytokine production after secondary LPS challenge of macrophages pretreated with TNF or LPS. Collectively, these results show that TNF-induced cross-tolerance is associated with diminished TLR4 signaling and the induction of known inhibitors of TLR4 signaling, such as A20.
GSK3 mediates TNF-induced cross-tolerance
We sought to further investigate mechanisms by which TNF induces macrophage tolerance and next tested the effects of a panel of inhibitors of pathways known to regulate macrophage cytokine production. TNF-induced cross-tolerance was reversed in a dose-dependent manner by the GSK3 inhibitor SB216763 (Fig. 4a) . In contrast, LPSinduced tolerization of IL-6 was not affected by SB216763. We next analyzed GSK3 activity and its regulation by TNF in human macrophages. GSK3 is constitutively active in most cell types, including macrophages [16] [17] [18] . Immunoblot analysis showed only modest or transient changes in serine-or tyrosine-phosphorylation of GSK3 (which are associated with changes in activity) after 3-24 h of treatment with TNF or LPS (Supplementary Fig. 7) . To further assess the effects of TNF on overall GSK activity, we used another approach to monitor GSK3 activity by measuring its substrate β-catenin, which is rapidly degraded after GSK3-mediated phosphorylation and is stabilized when GSK3 is inactivated. Consistent with the high basal GSK3 activity reported for human macrophages 17,18 , we did not detect β-catenin protein at baseline (Fig. 4b) despite high expression of β-catenin mRNA (data not shown). We observed massive upregulation of β-catenin when GSK3 was inhibited with SB216763 but observed minimal and transient increases in β-catenin expression after 3-24 h of treatment with LPS or TNF (Fig. 4b) . Thus, GSK3 remained active in TNF-treated macrophages and could contribute to TNF-mediated effects.
Although TNF seemed not to substantially regulate the overall phosphorylation or activity of GSK3, TNF increased nuclear expression of GSK3β (Fig. 4c) , thus facilitating the access of GSK3β to new substrates. Moreover, nuclear GSK3 was active in TNF-treated cells, as assessed by kinase assays (Fig. 4d) . Thus, we sought to more rigorously test the role of GSK3 in mediating TNF-induced crosstolerance. First, we found that LiCl, which inhibits GSK3 by a different mechanism than does SB216763, also potently reversed TNF-induced cross-tolerance while having no apparent effect on LPS-induced tolerance (Fig. 4e) . We confirmed and extended those results by genetic approaches. Downregulation of GSK3β by RNA-mediated interference restored the production of IL-6 in TNF-tolerized human primary macrophages but not in LPS-tolerized human primary macrophages ( Fig. 4f and Supplementary Fig. 8a (P < 0.01) ). In addition, we used BMDMs from mice with myeloid-specific deletion of the gene encoding GSK3β 36 . TNF was not able to induce tolerance, as assessed by LPS-induced production of IL-6 and expression of the gene encoding TNF, in GSK3β-deficient BMDMs (P < 0.0001, compared with control BMDMs; Fig. 4g ), whereas LPS-induced tolerance was intact ( Fig. 4g  and Supplementary Fig. 8b) . Collectively, these results provide compelling evidence that TNF-induced cross-tolerance of LPS responses is mediated by GSK3. LPS-induced tolerance was not affected by suppression of GSK3, possibly because LPS induces additional redundant tolerance mechanisms.
GSK3 regulates A20 expression and NF-B signaling To determine the mechanism by which GSK3 mediates TNF-induced cross-tolerance, we investigated the role of GSK3 in the suppression 
A r t i c l e s
of TLR signaling in TNF-tolerized macrophages. Inhibition of GSK3 had no effect on the diminished LPS-induced MAPK activation in TNF-tolerized macrophages (Fig. 5a) . However, inhibition of GSK3 repressed the rapid resynthesis of IκBα observed after LPS stimulation of TNF-tolerized cells ( Fig. 5b and Supplementary Fig. 9 ; 72.4% less IκBα at 60 min (mean); P < 0.0001; n = 10), thereby extending the duration of IκBα protein downregulation and NF-κB signaling to a period similar to that in control nontolerized macrophages. 
In contrast, IκBα protein expression remained high in LPS-tolerized macrophages even when GSK3 was inhibited ( Fig. 5c; 15.3% less IκBα at 60 min (mean)), consistent with the lack of reversal of LPS-induced tolerance by inhibition or ablation of GSK3 (Fig. 4) . These results suggest that GSK3 is required for the rapid termination of NF-κB pathway signaling by newly synthesized IκBα in TNF-tolerized macrophages. IκBα-mediated repression of NF-κB signaling after activation is a wellestablished inhibitory mechanism by which newly synthesized IκBα not only traps NF-κB proteins in the cytoplasm but also translocates to the nucleus and facilitates the removal of NF-κB subunits from selected gene promoters and subsequent export of NF-κB to the cytoplasm 34 . We detected substantial nuclear accumulation of resynthesized IκBα 90 min after stimulation of TNF-tolerized macrophages with LPS, and this nuclear accumulation was abrogated when GSK3 was inhibited (Fig. 5d) . In addition, chromatin-immunoprecipitation analysis showed that LPS-induced recruitment of the NF-κB subunit p65 to the endogenous IL6 and TNF promoters was much lower in TNF-induced tolerant cells (Fig. 5e) . Consistent with higher IL6 expression (Fig. 4a) , occupancy of the IL6 promoter by NF-κB p65 was enhanced when GSK3 was inhibited (Fig. 5f) . Collectively, these results suggest that GSK3 mediates TNF-induced tolerance at least in part by promoting the rapid reaccumulation of newly synthesized IκBα, thereby attenuating the expression of NF-κB-dependent genes.
We next examined the mechanism by which GSK3 accelerated and increased re-expression of IκBα protein after LPS stimulation of TNFtolerized macrophages. Transcription of the gene that encodes IκBα (NFKBIA) is rapidly and directly activated by NF-κB to engage rapid feedback inhibition after various activating stimuli 7, 37, 38 . Consistent with the intact but transient activation of NF-κB signaling (Fig. 5b) , IκBα mRNA was induced after LPS stimulation of TNF-tolerized macrophages (Fig. 6a) ; thus, NFKBIA is a gene that cannot be tolerized. The induction of IκBα mRNA by LPS did not differ substantially among naive, tolerized and SB216763-treated tolerized cells (Fig. 6a) , and thus the rapid reaccumulation of IκBα protein after LPS stimulation of tolerized cells (Fig. 5b) could not be explained by changes in the induction of IκBα mRNA. These results suggested that IκBα protein rapidly reaccumulated in TNF-tolerized LPS-stimulated cells because of less degradation, which is induced by phosphorylation mediated by the IκB kinase IKK. That idea was supported by the finding that LPS-induced activation of IKKβ was lower in TNF-tolerized cells (Fig. 6b) , which provides an explanation for less degradation of IκBα. In TNF-tolerized cells, inhibition of GSK3 partially but consistently reversed the attenuation of LPS-induced IKKβ activation, which indicated that GSK3 regulates LPS-induced signaling upstream of IKKβ. In contrast, in LPS-tolerized macrophages, inhibition of GSK3 did not reverse the attenuation of LPS-induced IKKβ activation (Fig. 6b) , consistent with the preservation of IκBα protein (Figs. 5c and 6b) .
Because activation of IKKβ is regulated by A20, which was linked to TNF-induced cross-tolerance (Fig. 3d) , we assessed the role of GSK3 in A20 expression. Inhibition of GSK3 suppressed the TNFinduced expression of A20 (Fig. 6c and Supplementary Fig. 6 ; mean inhibition 87%; n = 6). GSK3 inhibition also diminished the TNFinduced expression of A20 mRNA (Supplementary Fig. 10a ). In contrast, inhibition of GSK3 had a smaller effect on LPS-induced expression of A20 (Fig. 6c and Supplementary Fig. 6 ; mean inhibition 27%; n = 4). Other chemical inhibitors had no effect on A20 expression (Supplementary Fig. 10b) , and inhibition of GSK3 had minimal effects on the expression of IRAK-M and SHIP-1 ( Fig. 6c  and Supplementary Fig. 6 ), which demonstrates the specificity of this regulation. The idea of a role for GSK3 in TNF-induced sustained A20 expression was further supported by genetic evidence showing lower A20 expression when GSK3 expression was knocked down by RNA-mediated interference (Fig. 6d) . These results indicate that GSK3 regulates LPS-induced NF-κB signaling in TNF-pretreated macrophages in part by mediating TNF-induced, sustained accumulation of A20. A r t i c l e s TNF and GSK3 regulate chromatin accessibility A hallmark of LPS-induced tolerance is the acquisition of genespecific chromatin modifications that suppress the expression of tolerized genes. A potent mechanism of LPS-induced gene-specific tolerance is less accessibility of the chromatin of tolerized genes secondary to defective LPS-induced remodeling of the nucleosome, which leads to a failure to overcome a nucleosome-imposed barrier to gene transcription 5 . We tested the effects of pretreatment with TNF on chromatin accessibility at the IL6 locus in primary human macrophages by the restriction-enzyme accessibility assay, a well-established method for measuring chromatin accessibility at endogenous gene loci 7, 39 . As expected, cleavage at BsrBI restrictionendonuclease sites upstream of the IL6 transcription start site (Fig. 7a) was increased substantially by stimulation of naive cells with LPS, as detected by the induction of larger amounts of rapidly migrating cleaved DNA fragments (Fig. 7b) . LPS-induced cleavage at BsrBI sites was attenuated in TNF-tolerized cells (Fig. 7b) . Thus, similar to pretreatment with LPS, pretreatment with TNF suppressed the LPS-induced nucleosome remodeling that is required for effective induction of IL6 expression 40 . Inhibition of GSK3 in TNF-tolerized cells partially restored BsrBI accessibility (Fig. 7b) , which correlated with the restoration of IL6 expression (Fig. 4) and recruitment of NF-κB p65 to the IL6 locus (Fig. 5f) . These results show that TNF regulated chromatin accessibility at an inflammatory gene locus and that GSK3 mediated TNF-induced cross-tolerance by coordinated suppression of signaling and chromatin accessibility in response to secondary LPS challenge (Supplementary Fig. 11 ).
DISCUSSION
Induction of cross-tolerance to endotoxin by endogenous cytokines has not been investigated mechanistically, and the signaling pathways and molecules that are important for inducing tolerization are unknown. In this study we found that TNF induced tolerance in primary human and mouse macrophages and conferred protection from endotoxin toxicity and lethality in vivo. Hyporesponsiveness of the production of inflammatory cytokines by macrophages in response to secondary LPS challenge was mediated by the coordinated action of two inhibitory mechanisms: suppression of TLR-induced signaling and suppression of chromatin remodeling. Both inhibitory mechanisms were dependant on GSK3, which suppressed chromatin accessibility and promoted rapid termination of TLR-induced NF-κB signaling by augmenting negative feedback mediated by A20 and IκBα. Thus, the mechanism of TNF-induced tolerance is partially distinct from that of TLR-induced tolerance, in which NF-κB signaling is entirely blocked and GSK3 does not have a nonredundant role. Our findings have identified an unexpected homeostatic function of TNF and have demonstrated the role of GSK3 in controlling signaling and chromatin-remodeling pathways important for macrophage tolerance and, thus, the regulation of cytokine production and inflammation.
On balance, TNF is regarded as an activating, inflammatory and potentially toxic cytokine 41 . However, increasing evidence suggests a dual role for TNF, which can promote or suppress inflammation depending on timing and context [8] [9] [10] [11] [12] [13] [42] [43] [44] . The mechanisms that underlie the immunoregulatory functions of TNF are not well understood. Our results have shown that TNF serves a protective and homeostatic function in the earliest phases of innate responses by inducing macrophage tolerance. TNF-induced cross-tolerance will attenuate the activation of cells that are not directly exposed to microbial ligands during the initial stages of infection and during sterile inflammation [30] [31] [32] . TNF-induced feedback inhibitory mechanisms are clearly insufficient to adequately restrain chronic inflammation in autoimmune diseases such as rheumatoid arthritis, possibly because the efficacy of these mechanisms is compromised by other cytokines such as interferon-γ 33 , or by hypomorphic allelic variants of genes important for tolerance, such as variants of the gene encoding A20 that have been linked to several autoimmune and inflammatory diseases 45, 46 . Overall, our findings highlight the importance of the homeostatic functions of TNF.
One notable aspect of tolerance induced by both TLRs and TNF is the coordinated suppression of TLR-induced signaling and of chromatin modifications required for the induction of downstream genes encoding inflammatory molecules. It is likely that these two inhibitory mechanisms act together to fine-tune the amplitude and pattern of gene expression in restimulated tolerized cells. TNFmediated tolerization altered the kinetics of activation of NF-κB; such changes in kinetics are associated with altered patterns of gene activation 47, 48 . Published work has suggested that the key determinants of the amplitude and kinetics of NF-κB activation are cellular A20 concentrations present at the time of cell stimulation and the kinetics of IκBα protein re-expression after stimulation 37 . TNF gradually increased cellular A20 concentrations, which may explain the slow development of TNF-induced tolerance in human macrophages, and accelerated resynthesis of IκBα after subsequent TLR4 stimulation. The transient burst of TLR-induced NF-κB signaling observed in TNF-tolerized cells can contribute to the induction of nontolerized genes, such as the early-response gene NFKBIA, which is rapidly activated by NF-κB with minimal additional activation requirements 7, 38 . In contrast, a shortened duration of NF-κB signaling would be insufficient to activate secondary response genes such as IL6 that require later phases of NF-κB activity, after chromatin remodeling has occurred 40, 47 .
In naive macrophages, GSK3 is constitutively active and, depending on the context, can augment the production of proinflammatory cytokines after acute stimulation 17, 18 . In contrast, in tolerized cells that have been exposed to TNF for longer periods, there was a switch in GSK3 function such that GSK3 mediated suppression of the expression of inflammatory cytokines that is associated with macrophage tolerance. One mechanism by which this switch in GSK3 function was achieved was higher GSK3-mediated expression of A20 and IκBα, which themselves are encoded by NF-κB-activated genes. Thus, during tolerization, GSK3 still supports the expression of NF-κB target genes, but a shift toward high expression of genes involved in feedback inhibition of NF-κB results in attenuation of the classical inflammatory NF-κB-mediated response. Such shifts in the balance between activation and feedback inhibition of NF-κB signaling depending on prior environmental cues, such as prolonged TNF treatment, help to explain the context-dependent and often paradoxical effects of GSK3 on NF-κB signaling that have been reported 19, [25] [26] [27] [28] [29] . TNF did not markedly change basal GSK3 activity or its phosphorylation in macrophages but instead promoted nuclear localization of active GSK. GSK3-mediated phosphorylation of its substrates requires previous priming phosphorylation by a different kinase 16 , and TNF induces sustained signaling and phosphorylation of various cellular proteins in macrophages 49 . Thus, TNF probably alters cellular responses to GSK3 signaling at least in part by promoting access to, and inducing priming phosphorylation of, new substrates.
Similarities between TNF-induced cross-tolerance and classical LPS-induced endotoxin tolerance 4 include the functional state of 'tolerized' macrophages and diminished TLR4 signaling and chromatin remodeling after subsequent LPS challenge. However, crosstolerance induced by a heterologous receptors such as TNFRs differs A r t i c l e s from the desensitization of TLR4 that occurs after repeated stimulation of TLR4 by LPS. Initial LPS stimulation induces additional tolerance mechanisms such as downregulation of the cell surface expression of TLR4 and decoupling of TLR4 from the adaptor MyD88, which may explain the stronger and more rapid induction of tolerance by LPS, and the nearly complete block in NF-κB activation in LPS-tolerized cells. The induction of a more diverse set of partially redundant tolerance mechanisms by LPS may explain why suppression of GSK3 had little effect on LPS-induced tolerance. Indeed, LPS induced A20 expression mostly independently of GSK3. Although induction of A20 protein by TNF was delayed and occurred after the resolution of the well-characterized early phase of TNF signaling, there is partial overlap among tolerance mechanisms 4 and mechanisms that attenuate the initial phase of inflammatory responses. It is possible that mechanisms involved in attenuating the initial phase of inflammatory signaling and gene expression persist and contribute to hyporesponsiveness to secondary challenge.
The early phase of TNF-induced signaling and gene induction has been well characterized and linked to acute inflammatory responses. Studies characterizing later phases of TNF responses in macrophages suggest a more complex role for TNF, with induction of responses by type I interferons and the transcription factor STAT1 and differentiation into multinucleated cells 49 . In this study, we have extended that more nuanced understanding of the role of TNF in macrophages by demonstrating TNF-mediated induction of a potent feedback mechanism that suppresses the production of inflammatory cytokines. Our findings provide insights that can be exploited therapeutically to boost the suppressive and homeostatic functions of TNF while maintaining host defense in infectious and inflammatory settings.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
Note: Supplementary information is available on the Nature Immunology website.
